A panel of thoracic oncologists introduce themselves and discuss biomarker testing strategies and the diagnosis of HER2-mutated non–small cell lung cancer (NSCLC).
Alissa Cooper, MD, reviews new data for established and emerging antibody-drug conjugate targets in non–small cell lung cancer and argues that payload innovation and better patient selection are the field's greatest needs.